Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia

Piers Blombery, MBBS, Ella R Thompson, PhD BSc, Xiangting Chen, PhD, Tamia Nguyen, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, David Alan Westerman, MBBS, FRCPA, FRACP, John F. Seymour, Constantine S. Tam, MBBS, MD, Michael A Dengler, PhD, David C.S. Huang, MBBS MRCP PhD, Andrew Wei, MBBS,PhD, Andrew W Roberts, MBBS

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-137775

Published: 2020

Journal Articles

High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia

Ella R Thompson, PhD BSc, Tamia Nguyen, Yamuna Kankanige, PhD, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Rachel Thijssen, PhD, Paul Sung-Hao Yeh, MBBS, FRCPA, FRACP, Constantine S. Tam, MBBS, MD, John F. Seymour, Andrew W Roberts, MBBS, David Alan Westerman, MBBS, FRCPA, FRACP, Piers Blombery, MBBS

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-137411

Published: 2020

Journal Articles

Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL

Danielle M. Brander, MD, John F. Seymour, MBBS, PhD FRACP, Thomas J. Kipps, MD PhD, Shuo Ma, MD PhD, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Michael Y. Choi, MD, Kathryn Humphrey, BSc, Abdullah Al Masud, PhD, Ruby Nandam, RN, MSN, Amanda Jacobson, PhD, Andrew W. Roberts, MBBS, PhD

Blood (2019) 134 (Supplement_1): 3036.

https://doi.org/10.1182/blood-2019-126508

Published: 2019

Journal Articles

Long Term Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers

Joanne Davis, PhD, Sasanka M Handunnetti, MBBS, Chia Sharpe, Gillian Turner, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD FRACP, Constantine S. Tam, MBBS, MD, David Ritchie, MD PhD, Rachel Koldej

Blood (2019) 134 (Supplement_1): 2791.

https://doi.org/10.1182/blood-2019-122974

Published: 2019

Journal Articles

BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib

Blood (2019) 134 (Supplement_1): 170.

https://doi.org/10.1182/blood-2019-125488

Published: 2019

Journal Articles

Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax

Piers Blombery, MBBS, Ella Thompson, PhD BSc, Tamia Nguyen, Xiangting Chen, PhD, Michelle McBean, Richard W Birkinshaw, PhD, Peter E Czabotar, PhD, Rachel Thijssen, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, John F. Seymour, MBBS, PhD FRACP, David Alan Westerman, MBBS, FRCPA, FRACP, David C.S. Huang, MBBS MRCP PhD, Andrew W. Roberts, MBBS, PhD

Blood (2019) 134 (Supplement_1): 171.

https://doi.org/10.1182/blood-2019-125457

Published: 2019

Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Piers Blombery, MBBS, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, David Ritchie, MD PhD, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD FRACP, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 3999.

https://doi.org/10.1182/blood-2019-126396

Published: 2019

Journal Articles

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Rishu Agarwal, Mark A. Dawson, PhD MBBS, Sarah-Jane Dawson, MD PhD, Rachel Koldej, David Ritchie, MD PhD, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 756.

https://doi.org/10.1182/blood-2019-126619

Published: 2019

Journal Articles

High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study

Constantine S. Tam, MBBS, Judith Trotman, MBChB, Stephen Opat, MD, Paula Marlton, MBBS, Gavin Cull, MBBS DM FRACP FRCPA, David Simpson, MBChB, FRACP, FRCPA, Matthew Ku, MBBS, David Ritchie, MD PhD, Emma Verner, FRACP, FRCPA, MBBS, Sumita Ratnasingam, MBBS, Mary Ann Anderson, MBBS, Peter Wood, MD FRACP, FRCPA, MBBS, Mark Kirschbaum, MD, Lai Wang, PhD, Ling Xue, Jianxin Yang, Eric Hedrick, John F Seymour, Andrew W. Roberts

Blood (2016) 128 (22): 1216.

https://doi.org/10.1182/blood.V128.22.1216.1216

Published: 2016

Journal Articles

Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Constantine S. Tam, MBBS, Stephen Opat, MD, Gavin Cull, MBBS DM FRACP FRCPA, Judith Trotman, MBChB, David Gottlieb, MBBS MD FRACP FRCPA, David Simpson, MBChB, FRACP, FRCPA, Paula Marlton, MBBS, Mary Ann Anderson, MBBS, Matthew Ku, MBBS, David Ritchie, MD PhD, Sumita Ratnasingam, MBBS, Bradley Augustson, Mark Kirschbaum, MD, Lai Wang, PhD, Ling Xue, Jianxin Yang, Eric Hedrick, John F Seymour, Andrew W. Roberts

Blood (2016) 128 (22): 642.

https://doi.org/10.1182/blood.V128.22.642.642

Published: 2016

Journal Articles

Clinicopathological Features and Outcomes of Progression for Chronic Lymphocytic Leukaemia (CLL) Treated with the BCL2 Inhibitor Venetoclax

Thomas E Lew, Mary Ann Anderson, MBBS, Constantine S. Tam, MBBS, David C.S. Huang, MBBS, MRCP, PhD, Surender Juneja, MD FRCPA, David A Westerman, MBBS, FRACP, FRCPA, John F Seymour, Andrew W. Roberts, MBBS, PhD

Blood (2016) 128 (22): 3223.

https://doi.org/10.1182/blood.V128.22.3223.3223

Published: 2016

Journal Articles

Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Constantine Tam, MBBS, MD, Mary Ann Anderson, MBBS, David S. Ritchie, MDPhD, E. Henry Januszewicz, MBBS, Dennis Carney, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD

Blood (2015) 126 (23): 2939.

https://doi.org/10.1182/blood.V126.23.2939.2939

Published: 2015

Journal Articles

A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

John F. Gerecitano, MD, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD, William G. Wierda, MD, Brad S. Kahl, MD, John M. Pagel, MD PhD, Soham Puvvada, MD, Thomas J. Kipps, MD PhD, Mary Ann Anderson, MBBS, Martin Dunbar, DrPH, Ming Zhu, PhD, Lori Gressick, BS, Lindsay Wagner, BS, Su Young Kim, MD, Sari Heitner Enschende, MD, Rod A. Humerickhouse, MD PhD, Matthew S. Davids, MD

Blood (2015) 126 (23): 254.

https://doi.org/10.1182/blood.V126.23.254.254

Published: 2015

Journal Articles

Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study

Shuo Ma, MD, Danielle M. Brander, MD, John F. Seymour, MBBS, PhD, Thomas J. Kipps, MD PhD, Jacqueline C. Barrientos, MD, Matthew S. Davids, MD, Mary Ann Anderson, MBBS, Michael Y. Choi, MD, Constantine S. Tam, MBBS, Tanita Mason-Bright, Betty Prine, Wijith Munasinghe, PhD, Ming Zhu, PhD, Su Young Kim, MD, Rod A. Humerickhouse, MD PhD, Andrew W. Roberts, MBBS, PhD

Blood (2015) 126 (23): 830.

https://doi.org/10.1182/blood.V126.23.830.830

Published: 2015

Journal Articles

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Constantine Tam, MBBS, MD, Andrew P Grigg, MBBS MD, Stephen Opat, MBBS, Matthew Ku, MBBS, Michael Gilbertson, MBBS, Mary Ann Anderson, MBBS, John F. Seymour, MBBS, PhD, David S. Ritchie, MDPhD, Carmen Dicorleto, Belinda Dimovski, Eric Hedrick, Jianxin Yang, Lai Wang, PhD, Lusong Luo, Ling Xue, Andrew W. Roberts, MBBS, PhD

Blood (2015) 126 (23): 832.

https://doi.org/10.1182/blood.V126.23.832.832

Published: 2015

Journal Articles

Selective Bcl-2 Inhibition With ABT-199 Is Highly Active Against Chronic Lymphocytic Leukemia (CLL) Irrespective Of TP53 Mutation Or Dysfunction

Mary Ann Anderson, MBBS, FRACP, FRCPA, Constantine C.S. Tam, MBBS, FRACP, FRCPA, John F. Seymour, MBBS FRACP, Anthony Bell, David A Westerman, MBBS, FRACP, FRCPA, FFSc, Surender Juneja, MD, David C.S. Huang, MB, BS, MRCP, PhD, Andrew W. Roberts, MBBS, PhD

Blood (2013) 122 (21): 1304.

https://doi.org/10.1182/blood.V122.21.1304.1304

Published: 2013

NARROW

BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia

High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia

Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL

Long Term Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers

BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib

Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study

Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Clinicopathological Features and Outcomes of Progression for Chronic Lymphocytic Leukaemia (CLL) Treated with the BCL2 Inhibitor Venetoclax

Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Selective Bcl-2 Inhibition With ABT-199 Is Highly Active Against Chronic Lymphocytic Leukemia (CLL) Irrespective Of TP53 Mutation Or Dysfunction

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only